Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 25, 2024 09:15 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study

Cyclacel announces completion of enrollment in the biomarker-enriched cohort of its Phase 2 study - Patients are preselected for C
March 19, 2024 16:05 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support...
March 13, 2024 16:05 ET | Source: Cyclacel

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
November 30, 2023 09:15 ET | Source: Cyclacel

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

Cyclacel regains compliance with Nasdaq listing rule after filing Form-10Q for the quarter ended September 30, 2023
December 30, 2020 07:00 ET | Source: Cyclacel

Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021

BERKELEY HEIGHTS, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...